The humoral immune response against human cytomegalovirus (CMV) was retrospectively investigated in >800 serum samples from 31 recipients of allogeneic bone marrow transplants. To this end, an ELISA ...

To obtain more information about the mechanisms of susceptibility to and the strength of anti-CMV immunoglobulin G (IgG) antibody response to CMV infection, we have performed a genome-wide association ...

After open-heart surgery post-transfusion mononucleosis developed in six patients who had had cytomegalovirus complement-fixing (CMV-CF) antibody before operation. Three of them showed an appreciable ...

This is a preview. Log in through your library . Abstract To evaluate the risk to nurses of childbearing age of acquiring cytomegalovirus (CMV) infection during the care of patients at high risk of ...

A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma Alemtuzumab appears ...

We evaluated cytomegalovirus (CMV) immunoglobulin M (IgM) titer in pregnant women with primary infection as a predictive factor for congenital infection. Maternal CMV antibody screening during the ...

Declining immune responsiveness with age may be driven by changes in immune cells — not by inflammation, as previously ...

A UCLA research team has found a new way to prompt the immune system to kill cells infected with cytomegalovirus (CMV), a life-threatening infection that is particularly deadly in immunocompromised ...

The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...

Antibodies that summon virus-engulfing white blood cells may play an important role in protecting infants from potentially serious congenital infection with human cytomegalovirus (HCMV), according to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...